Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System (09k003)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00968032 |
Recruitment Status :
Completed
First Posted : August 28, 2009
Results First Posted : March 9, 2011
Last Update Posted : June 2, 2011
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Foramen Ovale, Patent Heart Catheterization Heart Septal Defects, Atrial | Device: Nit-Occlud® PFO | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 63 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Single-center Non-comparative, Prospective Interventional Clinical Investigation on the Procedural Success and Safety of the Nit-Occlud® PFO Closure Device and Its Application System. |
Study Start Date : | July 2009 |
Actual Primary Completion Date : | May 2010 |
Actual Study Completion Date : | June 2010 |
- Device: Nit-Occlud® PFO
Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
- Number of Participants With a Successful Implantation. [ Time Frame: 6 weeks ± 2 weeks ]The implantation of the device under investigation in a single patient is defined as successful if delivery, placement and release of the device in a stable position is successful. The value will be compared to the number of patient enrolled.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Diagnosis of patent foramen ovale (PFO)
- Age between 18 and 65 years of both gender
- Ability to give written informed consent after being told the potential benefits and risks of entering the trial to understand the planned clinical study and able to participate in all follow-up procedures
- Signed informed consent
-
Presenting with neurological symptoms and at least one of the following clinical circumstances:
- Diagnosis of cryptogenic stroke based on clinical neurological examination
- Diagnosis of a transient ischemic attack (TIA) based on clinical neurological examination
- PFO defect with or without atrial septal aneurysm of a balloon stretched diameter less than 18 mm. PFO tunnel length less than 10 mm in TEE
- Mental and physical ability of patient to follow the protocol according to compliance to time schedule, treatment plan,completion of CRF pages and further study procedures.
Exclusion Criteria:
- PFO dimensions exceeding Inclusion criterium 5)
- Active endocarditis
- Presence of an infectious disease
- Vascular anatomy unable to accommodate the appropriate-sized sheath for device introduction
- Current arrhythmia, or history of arrhythmia
- Prior cardiac surgery, including implantation of active and non-active cardiac device (coronary stent is allowed)
- Confinement to bed (because of higher potential for clot formation)
- Heart abnormality other than PFO
- Accessory atrial defects
- Participation in an investigational drug or device trial within 30 days prior to selection, or current inclusion in any other clinical trial or research project
- Known allergy to nickel
- Known allergy to contrast agents
- Cancerogenic disease or malignant tumor, or other severe disease
- Intracardiac mass or vegetation
- Thrombus at the intended site of implant or documented evidence of venous thrombus in the vessel to which access to the defect is gained
- Unable to tolerate Aspirin or Clopidogrel, and/or antibiotic prophylaxis for at least three months following the procedure
- Pregnant or breast feeding female patients
- Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this trial or will not comply with requirements of the study
- Subjects who are imprisoned (according to MPG § 20.3)
- Patients who are lawfully kept in an institution

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00968032
Germany | |
Cardio-Vascular Centre, Sankt Kathrinen | |
Frankfurt, Germany, 60389 |
Principal Investigator: | Horst Sievert, Prof. Dr. | Cardio-Vascular Centre, Sankt Kathrinen, Frankfurt, Germany |
Responsible Party: | Christof Schmeer head of quality assurance pfm group, pfm medical ag |
ClinicalTrials.gov Identifier: | NCT00968032 |
Other Study ID Numbers: |
09k003 |
First Posted: | August 28, 2009 Key Record Dates |
Results First Posted: | March 9, 2011 |
Last Update Posted: | June 2, 2011 |
Last Verified: | May 2011 |
PFO Patent Foramen Ovale |
Heart Septal Defects Foramen Ovale, Patent Heart Septal Defects, Atrial Heart Defects, Congenital |
Cardiovascular Abnormalities Cardiovascular Diseases Heart Diseases Congenital Abnormalities |